News

John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.

Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.

The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.

Hatem Soliman, MD, explains how to test for HER2 status in patients with breast cancer.

The FDA plans to conduct a speedy review of an approval application for trifluridine plus tipiracil and bevacizumab for the treatment of metastatic colorectal cancer.

The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.

Data presented at the 2023 AACR Annual Meeting on treatment with BGB-3245 in advanced or refractory tumors with a mutation in the MAPK pathway support ongoing investigations of BGB-3245 in defined cohorts during the dose-expansion portion of a phase 1a/1b trial.

Omidubicel showed encouraging clinical benefit in a phase 3 study vs standard myeloablative umbilical cord blood in patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant. Now, the FDA has approved the agent for this indication.

In a presentation given during the 2023 National Comprehensive Cancer Network Annual Conference, Mitesh J. Borad, MD, discussed treatment options for advanced hepatocellular carcinoma.

Edwin Choy, MD, discusses adjuvant treatments for patients with gastrointestinal stromal tumors.

Positive data from the phase 3 KarMMA-3 study has led to multiple regulatory applications being accepted for ide-cel as a treatment option for patients with relapsed/refractory multiple myeloma.

Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.

During a live, virtual event, Thomas Hutson, DO, PharmD, discussed the case of a 54-year-old man with a history of metastatic renal cell carcinoma.

Using the recommended doses of 50 and 70 mg per day from a phase 1a trial of NXP800, the agent will be further evaluated in patients with platinum-resistant, ARID1a-mutated ovarian cancer.

The FDA has requested positive results from a second clinical study of SGX301 in patients with early stage cutaneous T-cell lymphoma before filing a new drug application.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.

The FDA has now granted OM-301 2 orphan drug designations for the treatment of patients with multiple myeloma and acute myeloid leukemia.

Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.

The effects of chemotherapy-induced myelosuppression for extensive-stage small cell lung cancer were assessed in a new study which used a real-world community oncology setting.

The phase 3 MAJIC study is underway to compare 2 frontline regimens for patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Ajay Nooka, MD, discussed findings from the phase 3 KarMMa-3 trial and the use of ide-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Results from the EARLY-MYO-BC trial assessing the pyrotinib’s cardiac impacts may help researchers select an appropriate anti-HER2 treatment when managing patients with HER2-positive breast cancer.

KEYNOTE-859 findings are under review by the FDA as the regulatory body considers an approval application for pembrolizumab plus chemotherapy for the treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Mirvetuximab soravtansine is being assessed in combination with bevacizumab as a treatment for patients with folate receptor-alpha-positive recurrent platinum-sensitive ovarian cancer.

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

Multiple cases of unacceptable toxicity requiring dose reductions have occurred in a phase 1 study of MT-0169 in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The FDA has placed a partial clinical hold on the study

Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.

A phase 2, open-label clinical trial is evaluating treatment with QBS72S in patients with histologically-confirmed breast cancer that has developed brain metastases after a prior cytotoxic chemotherapy regimen.